Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 8897 results

  1. Total hip arthroplasty using the superpath approach for osteoarthritis

    In development Reference number: GID-IPG10204 Expected publication date: TBC

    Interventional procedures guidance
    In development

  2. Interventional Correction of Superior Sinus Venosus Defect and Partial Anomalous Pulmonary Venous Drainage

    Awaiting development Reference number: GID-IPG10419 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  3. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-IPG10409 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  4. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  5. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

    Awaiting development Reference number: GID-TA11383 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development Reference number: GID-TA11494 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development Reference number: GID-TA11326 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development Reference number: GID-TA11161 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]

    Awaiting development Reference number: GID-TA11194 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]

    Awaiting development Reference number: GID-TA10957 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development Reference number: GID-TA11481 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]

    Awaiting development Reference number: GID-TA10797 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development